Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis

We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Alton, Eric W F W, Beekman, Jeffery M, Boyd, A Christopher, Brand, June, Carlon, Marianne S, Connolly, Mary M, Chan, Mario, Conlon, Sinead, Davidson, Heather E, Davies, Jane C, Davies, Lee A, Dekkers, Johanna F, Doherty, Ann, Gea-Sorli, Sabrina, Gill, Deborah R, Griesenbach, Uta, Hasegawa, Mamoru, Higgins, Tracy E, Hironaka, Takashi, Hyndman, Laura, McLachlan, Gerry, Inoue, Makoto, Hyde, Stephen C, Innes, J Alastair, Maher, Toby M, Moran, Caroline, Meng, Cuixiang, Paul-Smith, Michael C, Pringle, Ian A, Pytel, Kamila M, Rodriguez-Martinez, Andrea, Schmidt, Alexander C, Stevenson, Barbara J, Sumner-Jones, Stephanie G, Toshner, Richard, Tsugumine, Shu, Wasowicz, Marguerite W, Zhu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Cystic Fibrosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5284333/
https://www.ncbi.nlm.nih.gov/pubmed/27852956
http://dx.doi.org/10.1136/thoraxjnl-2016-208406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5284333/
https://www.ncbi.nlm.nih.gov/pubmed/27852956
http://dx.doi.org/10.1136/thoraxjnl-2016-208406

Ejemplares similares